SAMSUNG PHARM. Co., LTD. (001360.KS)
KRW 1603.0
(0.25%)
KRW 1603.0
(0.25%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -18.04 Billion KRW | -29.23% |
| 2022 | -13.96 Billion KRW | 23.04% |
| 2021 | -18.13 Billion KRW | -85.16% |
| 2020 | -9.79 Billion KRW | -87.64% |
| 2019 | -5.22 Billion KRW | -59.89% |
| 2018 | -3.26 Billion KRW | 52.54% |
| 2017 | -6.88 Billion KRW | 28.24% |
| 2016 | -9.58 Billion KRW | -412.61% |
| 2015 | -1.87 Billion KRW | 90.56% |
| 2014 | -19.81 Billion KRW | -73.59% |
| 2013 | -11.41 Billion KRW | -2208.16% |
| 2012 | 541.6 Million KRW | 18.79% |
| 2011 | 455.92 Million KRW | -79.87% |
| 2010 | 2.26 Billion KRW | 779.93% |
| 2009 | 257.44 Million KRW | -87.4% |
| 2008 | 2.04 Billion KRW | 679.93% |
| 2007 | -352.42 Million KRW | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | -2.15 Billion KRW | 58.52% |
| 2024 Q2 | -6.17 Billion KRW | -187.02% |
| 2023 Q3 | -3.41 Billion KRW | 10.83% |
| 2023 Q4 | -5.19 Billion KRW | -51.99% |
| 2023 Q1 | -5.6 Billion KRW | -9.83% |
| 2023 FY | -18.04 Billion KRW | -29.23% |
| 2023 Q2 | -3.82 Billion KRW | 31.64% |
| 2022 FY | -13.96 Billion KRW | 23.04% |
| 2022 Q1 | -233.92 Million KRW | 96.91% |
| 2022 Q2 | -5.98 Billion KRW | -2457.94% |
| 2022 Q3 | -2.46 Billion KRW | 58.73% |
| 2022 Q4 | -5.1 Billion KRW | -106.54% |
| 2021 Q3 | -5.33 Billion KRW | -88.05% |
| 2021 Q1 | -2.42 Billion KRW | 22.64% |
| 2021 FY | -18.13 Billion KRW | -85.16% |
| 2021 Q2 | -2.83 Billion KRW | -17.08% |
| 2021 Q4 | -7.57 Billion KRW | -41.84% |
| 2020 Q2 | -4.38 Billion KRW | -814.72% |
| 2020 Q4 | -3.13 Billion KRW | -53.46% |
| 2020 FY | -9.79 Billion KRW | -87.64% |
| 2020 Q1 | -479.55 Million KRW | 0.0% |
| 2020 Q3 | -2.04 Billion KRW | 53.43% |
| 2019 Q2 | -1.56 Billion KRW | -68.63% |
| 2019 Q1 | -930.79 Million KRW | 67.97% |
| 2019 FY | -5.22 Billion KRW | -59.89% |
| 2019 Q3 | -3.36 Billion KRW | -114.44% |
| 2018 Q4 | -2.9 Billion KRW | -47.03% |
| 2018 Q2 | 68.56 Million KRW | 127.44% |
| 2018 FY | -3.26 Billion KRW | 52.54% |
| 2018 Q1 | 30.14 Million KRW | 100.99% |
| 2018 Q3 | -1.97 Billion KRW | -2982.44% |
| 2017 Q3 | -1.23 Billion KRW | -17.34% |
| 2017 Q2 | -1.05 Billion KRW | 31.48% |
| 2017 Q1 | -1.53 Billion KRW | 63.05% |
| 2017 FY | -6.88 Billion KRW | 28.24% |
| 2017 Q4 | -3.05 Billion KRW | -147.19% |
| 2016 Q4 | -4.15 Billion KRW | -42.36% |
| 2016 FY | -9.58 Billion KRW | -412.61% |
| 2016 Q3 | -2.92 Billion KRW | -38.05% |
| 2016 Q2 | -2.11 Billion KRW | -443.57% |
| 2016 Q1 | -389.41 Million KRW | -191.7% |
| 2015 Q1 | 309.87 Million KRW | 101.64% |
| 2015 Q2 | -491.5 Million KRW | -258.61% |
| 2015 Q3 | -2.09 Billion KRW | -326.6% |
| 2015 Q4 | 424.64 Million KRW | 120.25% |
| 2015 FY | -1.87 Billion KRW | 90.56% |
| 2014 Q4 | -18.86 Billion KRW | -2033.98% |
| 2014 Q3 | -883.84 Million KRW | -624.92% |
| 2014 Q2 | 168.37 Million KRW | 169.15% |
| 2014 Q1 | -243.5 Million KRW | 98.17% |
| 2014 FY | -19.81 Billion KRW | -73.59% |
| 2013 Q2 | 1.2 Billion KRW | -0.52% |
| 2013 Q3 | -521.45 Million KRW | -143.29% |
| 2013 Q4 | -13.31 Billion KRW | -2452.89% |
| 2013 Q1 | 1.21 Billion KRW | 214.33% |
| 2013 FY | -11.41 Billion KRW | -2208.16% |
| 2012 Q2 | 1.05 Billion KRW | 86.25% |
| 2012 Q1 | 568.27 Million KRW | 1451.22% |
| 2012 Q3 | -25.85 Million KRW | -102.44% |
| 2012 Q4 | -1.05 Billion KRW | -3997.2% |
| 2012 FY | 541.6 Million KRW | 18.79% |
| 2011 FY | 455.92 Million KRW | -79.87% |
| 2011 Q3 | -1.07 Billion KRW | -246.79% |
| 2011 Q4 | 36.63 Million KRW | 103.41% |
| 2011 Q1 | 761.53 Million KRW | 193.39% |
| 2011 Q2 | 731.49 Million KRW | -3.94% |
| 2010 Q3 | 695.2 Million KRW | -51.63% |
| 2010 FY | 2.26 Billion KRW | 779.93% |
| 2010 Q2 | 1.43 Billion KRW | 51.57% |
| 2010 Q1 | 948.24 Million KRW | 1511.26% |
| 2010 Q4 | -815.42 Million KRW | -217.29% |
| 2009 Q2 | 433.47 Million KRW | -8.51% |
| 2009 Q3 | -708.67 Million KRW | -263.49% |
| 2009 Q1 | 473.78 Million KRW | -27.37% |
| 2009 FY | 257.44 Million KRW | -87.4% |
| 2009 Q4 | 58.85 Million KRW | 108.3% |
| 2008 Q1 | 599.1 Million KRW | 114.81% |
| 2008 Q2 | 549.33 Million KRW | -8.31% |
| 2008 FY | 2.04 Billion KRW | 679.93% |
| 2008 Q3 | 242.99 Million KRW | -55.76% |
| 2008 Q4 | 652.37 Million KRW | 168.47% |
| 2007 Q3 | -1.82 Billion KRW | -348.0% |
| 2007 Q2 | 735.43 Million KRW | 60.87% |
| 2007 Q4 | 278.89 Million KRW | 115.29% |
| 2007 FY | -352.42 Million KRW | 0.0% |
| 2007 Q1 | 457.14 Million KRW | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 364.53 Million KRW | 5049.433% |
| Dong-A Socio Holdings Co., Ltd. | 76.88 Billion KRW | 123.468% |
| Ildong Holdings Co., Ltd. | -79.56 Billion KRW | 77.323% |
| HANDOK Inc. | 12.57 Billion KRW | 243.436% |
| Kukje Pharma Co., Ltd. | -1.98 Billion KRW | -807.05% |
| Yuhan Corporation | 74.56 Billion KRW | 124.198% |
| Dong-A ST Co., Ltd. | 11.17 Billion KRW | 261.404% |
| Hanmi Pharm. Co., Ltd. | 224.88 Billion KRW | 108.023% |
| Hanall Biopharma Co.,Ltd | 3.05 Billion KRW | 690.385% |
| Ilyang Pharmaceutical Co.,Ltd | 14.35 Billion KRW | 225.728% |
| Dong Sung Bio Pharm.Co.,Ltd. | 596.4 Million KRW | 3125.224% |
| MYUNGMOON Pharm co.,Ltd | 963.76 Million KRW | 1972.086% |
| Hana Pharm Co., Ltd. | 27.03 Billion KRW | 166.746% |
| Yuyu Pharma, Inc. | 364.53 Million KRW | 5049.433% |
| Ilsung Pharmaceuticals Co., Ltd. | -7.75 Billion KRW | -132.625% |
| REYON Pharmaceutical Co., Ltd. | 4.03 Billion KRW | 547.302% |
| Aprogen pharmaceuticals,Inc. | -69.95 Billion KRW | 74.207% |
| JW Holdings Corporation | 143.66 Billion KRW | 112.559% |
| Ildong Pharmaceutical Co., Ltd. | -53.41 Billion KRW | 66.224% |
| Chong Kun Dang Pharmaceutical Corp. | 246.59 Billion KRW | 107.317% |
| JW Pharmaceutical Corporation | 100.3 Billion KRW | 117.988% |
| Shin Poong Pharm.Co.,Ltd. | -47.39 Billion KRW | 61.93% |
| Hyundai Pharmaceutical Co., Ltd. | 6.92 Billion KRW | 360.469% |
| Samil Pharmaceutical Co.,Ltd | 6.47 Billion KRW | 378.82% |
| Jeil Pharmaceutical Co.,Ltd | 8.73 Billion KRW | 306.64% |
| Yuyu Pharma, Inc. | 364.53 Million KRW | 5049.433% |
| Kwang Dong Pharmaceutical Co., Ltd. | 48.76 Billion KRW | 136.997% |
| Daewoong pharmaceutical Co.,Ltd | 133.4 Billion KRW | 113.524% |
| JW Pharmaceutical Corporation | 100.3 Billion KRW | 117.988% |
| Yuhan Corporation | 74.56 Billion KRW | 124.198% |
| Jeil Pharma Holdings Inc | 20.92 Billion KRW | 186.245% |
| Yungjin Pharm. Co., Ltd. | 3.11 Billion KRW | 678.769% |
| Suheung Co., Ltd. | 42.99 Billion KRW | 141.964% |
| JW Pharmaceutical Corporation | 100.3 Billion KRW | 117.988% |
| Samjin Pharmaceuticals Co., Ltd. | 20.48 Billion KRW | 188.08% |
| Korea United Pharm Inc. | 54.94 Billion KRW | 132.835% |
| CKD Bio Corp. | -20.15 Billion KRW | 10.47% |
| Daewon Pharmaceutical Co., Ltd. | 32.23 Billion KRW | 155.976% |
| Dongwha Pharm.Co.,Ltd | 25.3 Billion KRW | 171.308% |
| Whan In Pharm Co.,Ltd. | 32.52 Billion KRW | 155.473% |
| Shin Poong Pharm.Co.,Ltd. | -47.39 Billion KRW | 61.93% |
| Chong Kun Dang Holdings Corp. | 33.14 Billion KRW | 154.432% |
| Boryung Corporation | 68.26 Billion KRW | 126.429% |
| Bukwang Pharmaceutical Co., Ltd. | -37.49 Billion KRW | 51.882% |
| Ilyang Pharmaceutical Co.,Ltd | 14.35 Billion KRW | 225.728% |
| JW Lifescience Corporation | 32.09 Billion KRW | 156.222% |